Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2007

Lonza to Spend More Than $64M in Manufacturing Site Expansion

  • Lonza reports that it is expanding its production capacities for highly potent APIs. The new manufacturing site will be built in Visp, Switzerland.

    Lonza will invest more than CHF 80 million, or about $64.38 million, and expects to hire approximately 40 new employees until 2009 due to this investment.

    “We are excited about being able to offer our customers a unique facility for the large-scale production of highly potent APIs,” notes Uwe Böhlke,head of Lonza Exclusive Synthesis (LES). “Additionally, this new facility supports the overall LES growth strategy as it provides Lonza with new commercial-scale production capacity in the face of high capacity utilization at Lonza’s existing cGMP small molecule facilities at Visp and Conshohocken, PA.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »